StockData

Grail vs Exagen

GRAL and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRAL and XGN compare

Grail is the larger company, worth 52 times as much as Exagen ($4.7B against $91.1M).

Grail grew revenue faster over the last twelve months (23.1% versus 20.8% for Exagen).

Exagen keeps more of each dollar of sales as profit, with a net margin of −26.6% compared with −237% at Grail.

Grail scores higher on the StockData Score (10 against 5 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRALXGN
Size and price
Market cap$4.7B$91.1M
Share price$105.88$3.76
Change, 1 year33.0%−58.3%
Change, 5 years–−65.9%
Beta (5Y)2.062.77
Employees910220
StockData Score
Total score10 (better)5
Valuation score1 (better)0
Growth score23 (better)
Performance score11
Health score6 (better)1
Dividend score00
Valuation
P/S28.6×1.3× (better)
P/B1.9× (better)7.5×
FCF yield−6.3% (better)−8.3%
Fair value–$3.42
Margin of safety–−9.9%
Growth
Revenue growth (TTM)23.1% (better)20.8%
Revenue growth, 5Y average–9.7%
Profitability
Gross margin–58.6%
Operating margin−338%−18.6% (better)
Net margin−237%−26.6% (better)
FCF margin−179%−10.7% (better)
Return on equity−16.1% (better)−114%
Return on invested capital−26.0% (better)−86.1%
Financial health
Debt / equity0.001.87 (better)
Interest coverage–−2.6×
Current ratio10.95 (better)3.18
Altman Z-score4.06 (better)−6.08
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.6%34.1%
Held by insiders11.0%29.2%
Insider net buying, 12 months−$38.3M−$769K (better)
Short interest, % of float20.1%4.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.